Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07214779 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Study acronym: MAESTRA 2
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 192 → 197 locations
  2. Trial sites expanded: 181 → 192 locations Interventions: INCB123667 (Drug), Investigator's choice of chemotherapy (Drug) to INCB123667 (Drug), Investigator's choice of chemotherapy (Drug) · Eligibility criteria expanded, about 15 words · Secondary endpoints: details revised at 3 of 10 entries Show 3 more changesShow less
    • Interventions: INCB123667 (Drug), Investigator's choice of chemotherapy (Drug) to INCB123667 (Drug), Investigator's choice of chemotherapy (Drug)
    • Eligibility criteria expanded, about 15 words
    • Secondary endpoints: details revised at 3 of 10 entries
  3. Trial sites expanded: 178 → 181 locationsv21
  4. Trial sites expanded: 169 → 178 locationsv20
  5. Trial sites reduced: 177 → 169 locationsv19
  6. Trial sites expanded: 172 → 177 locationsv18
  7. Trial sites expanded: 167 → 172 locationsv17
  8. Study sites: 165 to 167v16
  9. Trial sites expanded: 162 → 165 locationsv15
  10. Trial sites expanded: 157 → 162 locationsv14
  11. Study sites: 155 to 157v13
  12. Trial sites expanded: 139 → 155 locations Study sites revised (155)v12 Show 1 more changeShow less
    • Study sites revised (155)

    See this version in full on ClinicalTrials.gov ↗

  13. Study sites: 139 to 155v11
  14. Study sites: 137 to 139v10
  15. Study sites: 133 to 137v9
  16. Study sites: 132 to 133v8
  17. Study sites: 127 to 132v7
  18. Study sites: 123 to 127v6
  19. Study sites: 121 to 123v5
  20. Study sites: 110 to 121v4
  21. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 110 · Start date changed from estimate of Dec 1, 2025 to Dec 9, 2025v3 Show 2 more changesShow less
    • Study sites: 0 to 110
    • Start date changed from estimate of Dec 1, 2025 to Dec 9, 2025
  22. Study Status, Referencesv2
  23. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Incyte
94 trials monitored
See 9 trials at risk
Ovarian Cancer
1,245 trials monitored
See 80 trials at risk
The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.
Trial Details
NCT Number NCT07214779
Lead Sponsor Incyte Corporation
Collaborators: ENGOT Foundation, GOG Foundation
Conditions Ovarian Cancer
Enrollment 466 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov